0222.KL
Strong BuyFull HouseFLAGOptimax Holdings Berhad · Healthcare · Malaysia · $70M · Avg Vol: $25K/d
Full House: Strong business, sensible price, market agrees. The rare full house.
Insufficient evidence for a screen-pass. Optimax Holdings Berhad: clears the 50 floor (Q74/V60/M53) but not the 60 strong bar, and carries no corroborating filing signal (no net insider buying, no active buyback). Absence of evidence is neutral; nothing adverse is known.
ABOUT OPTIMAX HOLDINGS BERHAD
Read
Optimax Holdings Berhad, an investment holding company, engages in the provision of eye specialist services and related products in Malaysia.
FINANCIAL SUMMARY (MYR)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 108.0M | 114.0M | 127.7M | 135.7M | 7.9% | 139.4M | 151.9M | 157.4M | 7.7% |
| EPS (MYR) | 0.03 | 0.02 | 0.02 | 0.03 | -2.0% | 0.02 | 0.03 | 0.03 | 10.9% |
| Shares | 540.0M | 543.3M | 543.3M | 543.3M | +0.6% | 543.3M | — | — | — |
| Debt | 26.1M | 33.1M | 59.0M | 49.8M | 24.0% | 51.0M | — | — | — |
| Equity | 58.1M | 63.0M | 67.7M | 73.8M | 8.3% | — | — | — | — |
| Op CF | 27.1M | 25.3M | 23.5M | 31.7M | 5.4% | 31.4M | — | — | — |
| Inv CF | -11.2M | -9.9M | -22.5M | -6.5M | — | — | — | — | — |
| Fin CF | -16.1M | -17.5M | -0.6M | -21.1M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 0222.KL are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 0222.KL | Optimax Holdings Berhad(you) | $70M | 88 | Strong Buy |
| 0329.KL | Metro Healthcare Berhad | $51M | 89 | Strong Buy |
| 0363.KL | PMCK Berhad | $54M | 96 | Strong Buy |
| 0303.KL | Alpha IVF Group Berhad | $319M | 83 | Strong Buy |
| 0101.KL | TMC Life Sciences Berhad | $193M | 73 | Buy |
| 5878.KL | KPJ Healthcare Berhad | $3.0B | 64 | Hold |
| 0157.KL | Focus Point Holdings Berhad | $79M | 99 | Strong Buy |
| 5341.KL | LAC Med Berhad | $73M | 71 | Buy |
| 7148.KL | Duopharma Biotech Berhad | $306M | 93 | Strong Buy |
| 5555.KL | Sunway Healthcare Holdings Berhad | $6.1B | 34 | Sell |
Peer medians: ROE 9.2% · P/E 24.0x · Gross margin 33.8%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.